Equity Profile

REGN

Regeneron Pharmaceuticals, Inc.

Health CareBiotechnology$64.5B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

REGN Q2-2026 Earnings Preview

Context

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for serious diseases. Operating in the Health Care sector, Regeneron focuses on innovative treatments, particularly in areas like eye diseases, cancer, and inflammatory conditions, which are critical as healthcare needs continue to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+42.98%

Avg Stock Reaction

-0.40%

Last Quarter Recap

In Q1-2026, Regeneron reported an EPS of $9.47, surprising analysts by 50.7%. However, the stock dropped 6.21% the following day, indicating mixed market reactions despite strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given Regeneron's strong track record of beating EPS estimates. However, the lack of specific guidance raises uncertainty about future performance.

Bull Case

If Regeneron continues its trend of strong earnings surprises, it could lead to increased investor confidence and a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the recent stock performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Regeneron's history of beating EPS estimates, this figure will be crucial for determining market sentiment and stock performance.

What updates will be provided on the product pipeline?

Insights into new drug developments can significantly influence future revenue projections and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Regeneron's ability to innovate and expand its product pipeline, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Regeneron has consistently beaten EPS estimates, indicating strong operational efficiency.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Recent insider buying activity could signal confidence in the company's future performance.

Key Risk

If the product pipeline shows significant advancements, it could lead to a re-evaluation of growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Regeneron can maintain its impressive earnings trajectory amidst increasing competition and market pressures.

Bull Confirmed If

An EPS of $10.50 or higher would confirm the bull case, suggesting continued strong performance.

Bear Confirmed If

An EPS below $8.50 would confirm the bear case, indicating potential struggles in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±13.18%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±13.2% while REGN has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

41.1%

Calls (71K)P/C Ratio: 0.36Puts (80K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regeneron beats expectations, history suggests a potential stock increase of around 5.4%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

A miss could lead to a significant drop, with historical patterns suggesting a potential decline of around 6%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-LAJulia LetlowRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the performance of existing drugs in the market.
2Updates on regulatory approvals for new treatments.
3Insights into competitive pressures and market share.
4Management's outlook on future revenue growth.
5Details on R&D investments and their expected impact.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

REGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+42.98%

Avg Stock Reaction

-0.40%

Last Quarter Recap

In Q1-2026, Regeneron reported an EPS of $9.47, surprising analysts by 50.7%. However, the stock dropped 6.21% the following day, indicating mixed market reactions despite strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Regeneron continues its trend of strong earnings surprises, it could lead to increased investor confidence and a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the recent stock performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Regeneron's history of beating EPS estimates, this figure will be crucial for determining market sentiment and stock performance.

What updates will be provided on the product pipeline?

Insights into new drug developments can significantly influence future revenue projections and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Regeneron's ability to innovate and expand its product pipeline, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Regeneron has consistently beaten EPS estimates, indicating strong operational efficiency.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Recent insider buying activity could signal confidence in the company's future performance.

Key Risk

If the product pipeline shows significant advancements, it could lead to a re-evaluation of growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Regeneron can maintain its impressive earnings trajectory amidst increasing competition and market pressures.

Bull Confirmed If

An EPS of $10.50 or higher would confirm the bull case, suggesting continued strong performance.

Bear Confirmed If

An EPS below $8.50 would confirm the bear case, indicating potential struggles in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±13.18%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±13.2% while REGN has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

41.1%

Calls (71K)P/C Ratio: 0.36Puts (80K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regeneron beats expectations, history suggests a potential stock increase of around 5.4%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

A miss could lead to a significant drop, with historical patterns suggesting a potential decline of around 6%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-LAJulia LetlowRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the performance of existing drugs in the market.
2Updates on regulatory approvals for new treatments.
3Insights into competitive pressures and market share.
4Management's outlook on future revenue growth.
5Details on R&D investments and their expected impact.